Mubasher: Novo Nordisk on Monday announced that the Belgian biopharmaceutical company, Ablynx, has rejected an acquisition bid of EUR 2.6 billion ($3.11 billion) and refused to engage in any discussion regarding this deal.

“The proposal represents a 66% premium over Ablynx's three-month volume-weighted average price of EUR18.39 as of 5 January, and comprises EUR28 in cash for each share plus one contingent value right with total potential cash payments over time of up to EUR2.50 a share,” the Wall Street Journal reported.

The Danish giant Insulin maker’s offer, which was made on 22 December, came after a EUR 26.75 per share cash bid in 7 December was rejected.

Novo Nordisk sees this deal as a golden opportunity, believing that Ablynx's caplacizumab drug would be a strong addition to its hematology franchise.